{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/721-US20210060002A1(Pending) not sealed.pdf"}, "page_content": "6. The method of claim 1, wherein the subject is a mammal and the berbamine or its analogue is administered to the subject at a dose of about 20 mg/kg to about 50 mg/kg.\n\n7. The method of claim 1, wherein the subject is human berbamine or its analogue is administered to the subject a dose of about 20 mg/kg to about 50 mg/kg.\n\n8. The method of claim 1, wherein berbamine or its analogue is administered in combination with a compound selected from the group consisting of the following com- pounds and a derivative thereof:\n\nNO;\n\nits\n\na\n\nand\n\nat\n\nUS 2021/0060002 A1\n\nMar. 4 , 2021\n\n14\n\nwherein the flavivirus is Japanese encephalitis virus , Zika\n\ncontinued\n\nvirus or Dengue virus .\n\n10. The method of claim 9 , wherein the analogue of\n\nberbamine has a structure of Formula ( II ) , ( III ) , or ( IV ) :\n\nFormula ( II )\n\nFormula ( III )\n\nand\n\nor\n\n9. A method of inhibiting the entry of a flavivirus into host\n\ncells , comprising contacting the host cells with an effective\n\namount of berbamine or its analogue , berbamine has a\n\nNO2\n\nstructure of Formula ( I ) :\n\nFormula ( IV )\n\nFormula ( I )\n\nOH\n\nOH\n\nUS 2021/0060002 A1\n\nMar. 4, 2021\n\n14\n\nwherein the flavivirus is Japanese encephalitis virus, or Dengue virus.\n\n-continued\n\n10. The method of claim 9, wherein the analogue berbamine has a structure of Formula (II), (IID, or (IV):\n\nFormula (II)\n\nFormula No | | \u516d A N. aa \u516d \u300c\n\n9. Amethod of inhibiting the entry of a flavivirus into host cells, comprising contacting the host cells with an effective amount of berbamine or its analogue, berbamine has structure of Formula (1):\n\nFormula (1)\n\n| | sw 0. oases oN \u7ad9 Ch OO WN \u20180\n\nDO\n\na\n\nOH\n\nZika\n\nvirus\n\nof\n\n(II)\n\nCl\n\nFormula (IV)\n\nMar. 4 , 2021\n\nUS 2021/0060002 A1\n\n15\n\n11. The method of claim 10 , wherein the analogue of\n\n12. The method of claim 9 , wherein berbamine of its\n\nanalogue further inhibits the entry of an enterovirus and / or\n\nberbamine has the structure of Formula ( Ilb ) , ( IIIb ) , or\n\n( IVb ) :", "type": "Document"}}